Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the brugada syndrome

Circulation

Volumn 113, Issue 11, 2006, Pages 1393-1400

  Fish, Jeffrey M ^a   Welchons, Daniel R ^a   Kim, Young Sup ^b   Lee, Suk Ho ^c   Ho, Won Kyung ^c   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Action potentials; Antiarrhythmia agents; Arrhythmia; Reentry; Sudden death

Indexed keywords

DIMETHYL LITHOSPERMATE B; INWARDLY RECTIFYING POTASSIUM CHANNEL; PINACIDIL; SALVIA MILTIORRHIZA EXTRACT; UNCLASSIFIED DRUG; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; HERBACEOUS AGENT; PLANT EXTRACT; POTASSIUM CHANNEL; SODIUM; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; TERFENADINE; VOLTAGE GATED NA+ CHANNEL NA(V)1.5A; VOLTAGE-GATED NA+ CHANNEL NA(V)1.5A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRUGADA SYNDROME; CHANNEL GATING; CHINESE MEDICINE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DEFIBRILLATOR; DOG; ELECTROCARDIOGRAM; EPICARDIUM; EXTRASYSTOLE; FEMALE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; SALVIA MILTIORRHIZA; ST SEGMENT ELEVATION; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PLANT ROOT; STIMULATION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ARRHYTHMIA; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; DOGS; DRUG EVALUATION, PRECLINICAL; DRUGS, CHINESE HERBAL; ELECTROCARDIOGRAPHY; FEMALE; MALE; PINACIDIL; PLANT EXTRACTS; PLANT ROOTS; POTASSIUM CHANNELS; SALVIA MILTIORRHIZA; SODIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STIMULATION, CHEMICAL; TERFENADINE; VERAPAMIL;

EID: 33645812327     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.601690     Document Type: Article

References (20)

1. Antzelevitch C, Brugada P, Brugada J, Brugada R. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura; 2005.
2. Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342-1347.
3. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268-272.
4. Balser JR. The cardiac sodium channel: gating function and molecular pharmacology. J Mol Cell Cardiol. 2001;33:599-613.
5. Tan H. Biophysical analysis of mutant sodium channels in Brugada syndrome. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, eds. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura; 2004:26-41.
6. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation. 1999;100:1660-1666.
7. Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm. 2004;1:210-217.
8. Kur blocker, suppresses VT/VF in an experimental model of the Brugada syndrome. Circulation. 2004;110:III-193. Abstract.
9. Fish JM, Extramiana F, Antzelevitch C. Tedisamil abolishes the arrhythmogenic substrate responsible for VT/VF in an experimental model of the Brugada syndrome. Heart Rhythm. 2004;1(suppl 1):S158. Abstract.
10. Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. In: Kass R, Clancy CE, eds. Handbook of Experimental Pharmacology. New York, NY: Springer-Verlag; 2006:305-330.
11. Yoon JY, Ahn SH, Oh H, Kim YS, Ryu SY, Ho WK, Lee SH. A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes. Br J Pharmacol. 2004;143:765-773.
12. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation. 1998;98:1928-1936.
13. Yan GX, Shimizu W, Antzelevitch C. Characteristics and distribution of M cells in arterially-perfused canine left ventricular wedge preparations. Circulation. 1998;98:1921-1927.
14. Emori T, Antzelevitch C. Cellular basis for complex T waves and arrhythmic activity following combined I(Kr) and I(Ks) block. J Cardiovasc Electrophysiol. 2001;12:1369-1378.
15. Kohda H, Takeda O, Tanaka S, Yamasaki K, Yamashita A, Kurokawa T, Ishibashi S. Isolation of inhibitors of adenylate cyclase from dan-shen, the root of Salvia miltiorrhiza. Chem Pharm Bull (Tokyo). 1989;37:1287-1290.
16. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the Second Consensus Conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659-670.
17. Shimizu W, Antzelevitch C. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. J Electrocardiol. 1999;32(suppl):177-184.
18. Lu Y, Wang Z. Terfenadine block of sodium current in canine atrial myocytes. J Cardiovasc Pharmacol. 1999;33:507-513.
19. Shimizu W. Acquired forms of Brugada syndrome. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, eds. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura; 2004:166-177.
20. Brugada R. Brugada syndrome: role of genetics in clinical practice. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, eds. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura; 2004:130-139.